Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts

Rezolute, Inc. (NASDAQ:RZLT) has received an average rating of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $24.13.

Several research firms recently weighed in on RZLT. Maxim Group raised their target price on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. BTIG Research upped their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. Guggenheim initiated coverage on Rezolute in a report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $7.00 price target on shares of Rezolute in a research note on Friday, September 20th.

Rezolute Price Performance

Rezolute stock opened at $4.99 on Tuesday. The firm has a 50-day moving average of $5.12 and a 200-day moving average of $4.61. The company has a market cap of $289.14 million, a price-to-earnings ratio of -3.93 and a beta of 1.18. Rezolute has a one year low of $0.72 and a one year high of $6.19.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14). As a group, sell-side analysts expect that Rezolute will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Rezolute

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of Rezolute during the 1st quarter worth approximately $37,000. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute in the second quarter valued at approximately $45,000. MML Investors Services LLC acquired a new stake in Rezolute during the third quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Rezolute during the 3rd quarter worth $65,000. Finally, XTX Topco Ltd raised its holdings in Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after acquiring an additional 22,660 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.